Stock Analiz

Cytosorbents Corp CTSO

Medical/Dental Instruments · data as of November 13, 2026

$4.87Market cap $15M
Open the interactive analysis →

Cytosorbents Corp (CTSO) is a healthcare company listed in the US with a market value of about $15M. In the twelve months to June 30, 2026 it had revenue of $37M and net income of -$18M, a net margin of -48.9%.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -48%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.

About Cytosorbents

Cytosorbents is listed in the US and classified in medical/dental instruments. Revenue went from $41M in 2020 to $37M in 2025, a decline of about 2.0% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 43% over three years (dilution for shareholders).

Score: 0.2 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Profit margin improving

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.4
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-60.6%
Shareholder yield0.0%
Intrinsic value vs. price−80%

Growth and quality

Revenue growth (1 yr)4.1%
Revenue growth (5 yrs, per year)-2.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-65.2%
ROIC (5-yr avg.)-48.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$37M$37M$36M$31M$35M$43M$41M
Net income-$18M-$8M-$21M-$29M-$33M-$25M-$8M
Free cash flow-$9M-$13M-$15M-$22M-$34M-$18M-$6M
EPS (diluted)$-5.80$-2.60$-7.60$-13.00$-15.00$-11.40$-4.00
Net margin-48.9%-22.1%-58.2%-94.1%-94.6%-56.9%-19.1%
ROIC—-40.2%-40.0%-74.4%-56.9%-28.9%-11.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $47.50, 875% above the current price; targets range from $15.00 to $80.00; the consensus rating is “none”; expected EPS is $-4.40 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Cytosorbents stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Cytosorbents pay a dividend?

Not currently.

Is Cytosorbents a good stock to buy?

We do not give buy or sell advice. Cytosorbents scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.